DiaMonTech

Executive Summary

DiaMonTech is a German medtech company pioneering non-invasive glucose monitoring using patented mid-infrared laser spectroscopy. Unlike traditional finger-prick methods or invasive continuous glucose monitors (CGMs), DiaMonTech's technology measures blood glucose levels through the skin without needles, offering a pain-free and convenient solution for diabetes patients. The company has developed a handheld device and is working on a miniaturized sensor for integration into wearables, targeting both consumers and healthcare providers. Founded in 2015 and based in Berlin, DiaMonTech is positioned to address the growing global diabetes epidemic, where the demand for non-invasive monitoring is high. With a strong intellectual property portfolio and promising early studies, the company aims to disrupt the $20+ billion glucose monitoring market. DiaMonTech's progress to date includes successful proof-of-concept studies and the development of a functional prototype. The company is now focusing on clinical validation and regulatory approval to bring its devices to market. Key upcoming milestones include completion of a pivotal clinical trial for the handheld device, securing strategic partnerships for manufacturing or distribution, and initiating regulatory submissions in Europe and the US. If successful, DiaMonTech could become a leader in non-invasive glucose sensing, transforming diabetes management. However, challenges remain in achieving the required accuracy, miniaturization, and cost-effectiveness. The company's execution on these fronts will determine its commercial viability.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal clinical trial for DMT-Handheld device70% success
• Q2 2026Strategic partnership with major diabetes care company60% success
• Q1 2027CE marking submission for DMT-Handheld device80% success